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Non-Hodgkin lymphoma includes a heterogeneous group of
illnesses. The presentation may range from an isolated and
non-enlarging lymph node asymptomatic for many years, to
massive compromise of vital organs by infiltration that proceeds
with great speed. Further complexity is added by the variety of
anatomical sites which may be affected: most NHL involve nodal
and bone marrow disease, but significant numbers may involve the
brain, meninges, lungs, gastrointestinal tract, liver, kidneys,
skeleton, skin or other sites. In each case, there are distinctions
of prognosis according to the histologic grade and type.
During the period studied, there has been a well-documented
rise in the incidence of large B-cell lymphoma in patients more
than the age of 65 years (Hartge et al, 2004). This, together with the
ageing population generally has led to a marked rise in the number
of older patients with aggressive lymphoma for which only
relatively intensive chemotherapy will be curative. There has also
been an increase in the number of lymphomas associated with
impaired immunity, whether because of HIV or immunosuppres-
sion following organ transplantation. In addition, there are
recognised geographical differences in the incidence of different
lymphoma types; hence the picture is susceptible to the effects of
immigration as well.
The diagnosis of lymphoma depends upon a tissue biopsy and
its histology. The clinical presentation of the illnesses has not
changed greatly over time, with most appearing as nodal masses,
and some with manifestations of extra-nodal disease. There have
been notable advances in the techniques used to subdivide
lymphoma over the last 20 years, in particular monoclonal
antibodies to determine the cell of origin, whether B- or T-
lymphocyte, and the expression of a variety of cellular markers to
distinguish all the various categories within these, related to some
extent to their non-malignant counterparts in lymphocyte
ontogeny (Harris et al, 1999). Further refinement has come from
the use of cytogenetics to identify characteristic chromosomal
rearrangements, and molecular techniques to define the precise
nature of them, for example, the t(14;18)(q32;q21) rearrangement
of the Bcl-2 gene which is most often seen in follicular lymphoma,
or the t(11;14)(q13;q32) rearrangement of Cyclin-D1 seen in
mantle cell lymphoma. Yet, further refinement of the process is
now being achieved with the use of gene expression profiling to
build up detailed maps of genetic signatures, which have
prognostic, and potentially therapeutic significance (Alizadeh
et al, 2000; Rosenwald et al, 2002).
All these techniques have given a level of sophistication to
lymphoma classification, which has been helpful for planning
treatment and trials, but has had the less welcome effect of making
previous classifications redundant, and to some extent irrelevant.
The result is that beyond broad categories of ‘aggressive’ and
‘indolent’ it is difficult to make direct comparisons of the case mix
over the period under study. Given the very different prognoses for
the various subtypes of lymphoma this renders longditudinal data
of limited use.
TREATMENT
The variety of lymphoma types is mirrored in a range of
approaches to treatment. Thus, localised low-grade disease,
such as follicular, marginal zone or lymphocytic lymphoma
may be managed by excision alone, with or without local
radiotherapy, and disseminated low-grade disease is frequently
managed expectantly, until there is a specific indication for
treatment, such as a fall in the blood count, progressive nodal
enlargement, systemic symptoms or compression of internal
organs. Conversely, high-grade disease, such as diffuse large B-
cell or Burkitt lymphoma is usually treated with intensive
combination chemotherapy, sometimes using consolidation radio-
therapy to the sites of residual disease. Myeloablative treatment
may be used for recurrent disease, with autologous progenitor cell
rescue of the marrow, and in some subtypes allogeneic transplants
are used.
There have been significant developments in lymphoma
therapy during the period studied, although the rate of change
has probably increased more since 2000, making it likely that the
rise in survival figures will continue and perhaps accelerate.
The biggest single change in lymphoma therapy in the last
decade has been the introduction of treatment with monoclonal
antibodies, in particular those recognising CD20 on the B-cell
surface. Clinical trials conducted since the late 1990s have
shown marked benefit from the incorporation of anti-CD20
into treatment, both as a single agent and in combination
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such antibodies before 2000; hence it is unlikely that this
development influenced the figures greatly. There is now strong
evidence of a survival benefit from the use of combination
chemoimmunotherapy in the initial treatment of follicular (Herold
et al, 2003; Forstpointner et al, 2004; Marcus et al, 2005) and
diffuse large B-cell lymphoma (Coiffier et al, 2002; Habermann
et al, 2006), whereas lesser effects are seen in mantle cell
lymphoma, amounting to prolongation of remission without
substantial impact on overall survival (Lenz et al, 2005). Trials
are ongoing to determine the effects in the less common B-cell
lymphomas, such as Burkitt’s, lymphoplasmacytic and marginal
zone types. Further developments, such as the use of anti-CD20
conjugated to radionuclides for the selective delivery of radiation
are still being tested, as is the use of anti-CD20 maintenance
therapy, which seems to convey benefit in follicular lymphoma, at
least in second remission (van Oers et al, 2006).
The other major development in lymphoma treatment
during the period of study was the introduction of high-dose
therapy, with the aim of overcoming chemoresistance by admin-
istration of myeloablative doses, followed by rescue using
previously collected haemopoietic progenitor cells. At the begin-
ning of this period, the progenitor cells were collected in bone
marrow aspirates, but from the early 1990s there was a progressive
switch to the use of peripheral blood progenitors, mobilised by
chemotherapy followed by the use of granulocyte colony-
stimulating factor and harvested by leukapheresis. This approach
has the advantage of shortening the time to re-engraftment
and recovery, with consequent improvements in treatment-
related mortality, and the capacity to carry out such procedures
in older or less fit patients. There is evidence of survival benefit
from high-dose therapy in the second remission from both diffuse
large B-cell lymphoma (Philip et al, 1995) and follicular lymphoma
(Brice et al, 2000; Schouten et al, 2003), whereas in mantle cell
lymphoma the data suggest prolongation of remission without an
effect on survival (Dreyling et al, 2005). High-dose therapy has also
been used, with some suggestion of benefit, as part of initial
therapy for lymphoblastic (Sweetenham et al, 2001) and peripheral
T-cell lymphomas (Rodriguez et al, 2003), both types with a
relatively poor outlook after conventional treatment. Allogeneic
transplants, which depend upon engraftment of marrow from an
HLA-matched donor have been less commonly used in lymphoma.
They have more complex toxic effects, particularly graft-versus-
host disease, and the treatment-related mortality can be up to 30%,
but they may offer cures to the small number of patients fit enough
to have them carried out for low-grade lymphoma, which would
otherwise pursue a course of serial recurrences (Morris et al,
2004). There is, however, little evidence from prospective clinical
trials as yet.
The organisation of clinical services for lymphoma has largely
followed a dispersed model in England and Wales, with most
district hospitals managing cases locally, only referring to
specialist centres for uncommon types or those requiring intensive
and high-dose therapy. The National Institute for Clinical
Excellence published guidelines for the organisation of
services in haematologic malignancy in 2003; hence, these cannot
have directly influenced the data presented here, although
there were already changes taking place in service delivery
before publication of the guidelines, particularly central pathology
review. The need for more complex diagnostic subclassification
of NHL has increased as the role of treatments specific to
particular entities has emerged, for example, diffuse large B-cell
lymphoma must be rapidly distinguished from Burkitt lymphoma
to achieve the optimum outcome in both types. In clinical trials,
the results of treatment seem to differ little between smaller
units and specialist centres, although the proportion of patients
entering such trials varies greatly, and nowhere is above 10% of
incident cases.
DISCUSSION
The modest rise in survival figures over the period studied is
encouraging, although as already mentioned, it seems likely that
the rate of improvement may increase after 2000. The progress
made may be underrepresented, as the case-mix has changed
through the rising incidence of aggressive lymphoma in the older
population. The outcomes in this group are uniformly worse than
in younger patients, principally because the delivery of effective
treatment is often compromised by comorbidity. The rising
incidence of immunodeficiency-related lymphomas, which again
are more difficult to treat effectively, will also have had a small
negative effect.
The increments in survival during this period probably reflect
the more effective application of existing chemotherapy treatments
and better supportive care, particularly with antibiotics, blood
products and growth factors to manage the consequences of
myelosuppression during chemotherapy. Myeloablative therapy
for recurrent disease, although conveying survival benefits in
clinical trials is applicable only to a small minority of patients,
probably no more than 5% of the total with NHL; therefore is
unlikely to have had a major impact on survival across the whole
population.
The differences in outcome among the deprivation groups are in
keeping with the trends seen in most other tumour types. It is
likely that comorbidity, particularly related to cigarette smoking,
plays a significant role in this difference, as the outcome in NHL is
more dependant upon ability to withstand intensive systemic
treatment than for many tumour types. Patients with aggressive
lymphoma with significant cardiorespiratory illnesses are much
more prone to death as a result of treatment toxicity, or recurrent
lymphoma following premature cessation of therapy owing to life-
threatening complications or cumulative side effects. It is also
likely that the competing risks of cardiorespiratory or other
illnesses, more prevalent in deprived groups, are heightened
by the effects of systemic treatment in the relatively elderly
lymphoma population. Nutritional state is another determinant
of the capacity to receive intensive chemotherapy, and this too
will act to disadvantage the more deprived groups. Unfortunately
there is little clear evidence on these factors, as clinical trials
usually exclude patients unfit for intensive therapy. Other
factors, such as late presentation and reduced access to specialist
services probably play a less dominant role in the differences
according to deprivation: in general the dispersed model of
lymphoma services has produced good population-wide access to
care and there is little evidence to link time to diagnosis with
outcome in NHL. Aggressive lymphomas generally present with
sufficiently severe symptoms to promote rapid referral, although
survival with indolent lymphomas is little affected by the speed of
therapy. An exception to this may be immunodeficiency-related
lymphoma among immigrant populations. Outcomes in this group
are likely to be worse both because the risks of treatment are
greater and because of reduced access to complex medical
interventions.
In conclusion, the rising survival figures are welcome, and likely
to underrepresent the progress being made owing to changes in
case-mix. There are good reasons to expect the improvement to
continue and accelerate as monoclonal antibodies and new small
molecule therapies enter wider use. The differences in outcome
between wealthier and more deprived groups remain a source of
concern, but there are reasons to expect that these may begin to
decline as supportive care improves and cigarette smoking
becomes less prevalent. The implementation of NICE guidelines
for care of haematologic malignancy will largely consolidate a
process, which was already underway previously, but there may be
further benefits in terms of better histopathologic characterisation
that becomes more important as the specificity of treatment
increases.
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